[HTML][HTML] Acute myeloid leukemia: from biology to clinical practices through development and pre-clinical therapeutics

X Roussel, E Daguindau, A Berceanu… - Frontiers in …, 2020 - frontiersin.org
Recent studies have provided several insights into acute myeloid leukemia. Studies based
on molecular biology have identified eight functional mutations involved in leukemogenesis, …

Characterization of substrate and product specificity of the purified recombinant glycogen branching enzyme of Rhodothermus obamensis

X Roussel, C Lancelon-Pin, A Viksø-Nielsen… - … et Biophysica Acta (BBA …, 2013 - Elsevier
BACKGROUND: Glycogen and starch branching enzymes catalyze the formation of α(1→6)
linkages in storage polysaccharides by rearrangement of preexisting α-glucans. This …

Bendamustine plus rituximab in newly‐diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization …

…, D Roos‐Weil, D Chaoui, X Roussel… - British Journal of …, 2019 - search.ebscohost.com
The article focuses on study that evaluated the efficacy and safety of bendamustine plus
rituximab (BR) in symptomatic untreated patients with Waldenstr€ om macroglobulinaemia (WM)…

First‐line treatment of double‐hit and triple‐hit lymphomas: survival and tolerance data from a retrospective multicenter French study

…, P Coppo, S Malot, X Roussel… - American journal of …, 2021 - Wiley Online Library
Historically, double or triple hit lymphoma (DHL and THL) have poor outcomes with conventional
chemotherapy, but there is currently no guideline. We report the French experience in …

Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi‐institutional retrospective study of 77 cases from the French Innovative …

…, E Van Den Neste, S Ivanoff, X Roussel… - British Journal of …, 2017 - Wiley Online Library
Histological transformation ( HT ) to diffuse large B‐cell lymphoma ( DLBCL ) is a rare and
poorly reported complication of Waldenström macroglobulinaemia ( WM ). We performed a …

[HTML][HTML] Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia

…, C Nicod, R Haderbache, X Roussel… - … for Immunotherapy of …, 2022 - ncbi.nlm.nih.gov
… The fold change is presented on the x-axis (expressed as log2), and the p value (expressed
as the –log10 adjusted p value) is presented on the y-axis. Genes with log2 fold change > |1…

[HTML][HTML] Plasmacytoid Dendritic cells, a novel target in myeloid Neoplasms

X Roussel, F Garnache Ottou, F Renosi - Cancers, 2022 - mdpi.com
Simple Summary Plasmacytoid dendritic cells are the main type I interferon producing cells
in humans and are able to modulate innate and adaptive immune responses. Tumor …

[HTML][HTML] Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy …

…, R Haderbache, Y Salma, L Bouquet, X Roussel… - Cancer Gene …, 2021 - nature.com
Although chimeric antigen receptor CAR) T cell immunotherapies are an undeniable and
unequivocal success, knowledge obtained from the monitoring of the first clinical trials …

[HTML][HTML] Droplet digital PCR allows vector copy number assessment and monitoring of experimental CAR T cells in murine xenograft models or approved CD19 CAR T …

…, M Guiot, F Venet, P Sujobert, X Roussel… - Journal of Translational …, 2021 - Springer
… CEM-CAR and serial dilutions within the wild-type CEMT cell line and experimental CAR
T cells were analyzed by flow cytometry on a BD LSRFortessa™ X-20 cell analyzer after …

[HTML][HTML] CAR-T cells targeting IL-1RAP produced in a closed semiautomatic system are ready for the first phase I clinical investigation in humans

C Nicod, MN da Rocha, W Warda, X Roussel… - Current Research in …, 2023 - Elsevier
Purpose of the study The use of chimeric antigen receptor (CAR)-T cells has demonstrated
excellent results in B-lymphoid malignancies. The Advanced Therapy Medicinal Products (…